These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32172812)

  • 1. Role of Antithrombin III and Tissue Factor Pathway in the Pathogenesis of Sepsis.
    Sungurlu S; Kuppy J; Balk RA
    Crit Care Clin; 2020 Apr; 36(2):255-265. PubMed ID: 32172812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock.
    Gando S; Nanzaki S; Sasaki S; Aoi K; Kemmotsu O
    Crit Care Med; 1998 Dec; 26(12):2005-9. PubMed ID: 9875912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients.
    Mesters RM; Mannucci PM; Coppola R; Keller T; Ostermann H; Kienast J
    Blood; 1996 Aug; 88(3):881-6. PubMed ID: 8704245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Are there certified indications for the use of antithrombin III in intensive care].
    Kulka PJ; Tryba M; Lange S
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2001 Mar; 36(3):143-53. PubMed ID: 11324345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled trial of antithrombin III supplementation in fulminant hepatic failure.
    Langley PG; Hughes RD; Forbes A; Keays R; Williams R
    J Hepatol; 1993 Mar; 17(3):326-31. PubMed ID: 8315261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction.
    Inthorn D; Hoffmann JN; Hartl WH; Mühlbayer D; Jochum M
    Shock; 1997 Nov; 8(5):328-34. PubMed ID: 9361342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the tissue factor pathway in the pathogenesis and management of multiple organ failure.
    Smithies MN; Weaver CB
    Blood Coagul Fibrinolysis; 2004 May; 15 Suppl 1():S11-20. PubMed ID: 15166928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased production or increased turnover of antithrombin III in severe acquired coagulopathy?
    Schmidt B; Wais U; Pringsheim W; Witt I; Künzer W
    Klin Wochenschr; 1981 Dec; 59(24):1349-51. PubMed ID: 7321483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [[Antithrombin III concentrates in the treatmetn of sepsis and septic shock: indictions, limits and future prospects] ].
    Baudo F; de Cataldo F
    Minerva Anestesiol; 2000 Nov; 66(11 Suppl 1):3-23. PubMed ID: 11213542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coagulation inhibitors in sepsis and disseminated intravascular coagulation.
    Lee WL; Downey GP
    Intensive Care Med; 2000 Nov; 26(11):1701-6. PubMed ID: 11193281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies.
    Fourrier F; Chopin C; Goudemand J; Hendrycx S; Caron C; Rime A; Marey A; Lestavel P
    Chest; 1992 Mar; 101(3):816-23. PubMed ID: 1531791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock.
    Vervloet MG; Thijs LG; Hack CE
    Semin Thromb Hemost; 1998; 24(1):33-44. PubMed ID: 9515778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coagulation dysfunction in sepsis and multiple organ system failure.
    Nimah M; Brilli RJ
    Crit Care Clin; 2003 Jul; 19(3):441-58. PubMed ID: 12848314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathophysiology and therapy of sepsis-associated coagulation disorders].
    Knöbl P
    Wien Med Wochenschr; 2002; 152(21-22):559-63. PubMed ID: 12506679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches to the treatment of sepsis.
    O'Brien JM; Abraham E
    Clin Chest Med; 2003 Dec; 24(4):521-48, v. PubMed ID: 14710689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuing challenges of sepsis research.
    Crowther MA; Marshall JC
    JAMA; 2001 Oct; 286(15):1894-6. PubMed ID: 11597294
    [No Abstract]   [Full Text] [Related]  

  • 17. [Physiopathology of severe sepsis].
    Caille V; Bossi P; Grimaldi D; Vieillard-Baro A
    Presse Med; 2004 Feb; 33(4):256-61; discussion 269. PubMed ID: 15029017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense?
    van der Poll T; Lowry SF
    Shock; 1995 Jan; 3(1):1-12. PubMed ID: 7850574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombin concentrate use in sepsis-associated disseminated intravascular coagulation: re-evaluation of a 'pendulum effect' drug using a nationwide database.
    Tagami T
    J Thromb Haemost; 2018 Mar; 16(3):458-461. PubMed ID: 29316251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing a conceptual model on early opening of the microcirculation in severe sepsis and septic shock: a randomised controlled pilot study.
    van der Voort PH; van Zanten M; Bosman RJ; van Stijn I; Wester JP; van Raalte R; Oudemans-van Straaten HM; Zandstra DF
    Eur J Anaesthesiol; 2015 Mar; 32(3):189-98. PubMed ID: 25032942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.